Kenneth R Hallows MD PhD, FASN
Professor of Medicine; Chief, Division of Nephrology and Hypertension; Director, USC/UKRO Kidney Research Center / University of Southern California Keck School of Medicine
Join to View Full Profile
111 Colchester AveBurlington, VT 05401
Phone+1 802-847-0000
Dr. Hallows is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kenneth Hallows, MD, is a Nephrologist with medical education from the University of Rochester School of Medicine and Dentistry and Biophysics education from Brown University. After completing his residency and fellowship at the University of Pennsylvania Health System, he gained professional experience at the University of Pittsburgh School of Medicine and the Hospital of the University of Pennsylvania. Currently, Dr. Hallows serves as a Professor of Medicine, Chief of Nephrology and Hypertension, and the Director of the USC/UKRO Kidney Research Center at the Keck School of Medicine of USC. His expertise spans general nephrology, acute renal failure, and chronic kidney disease. He has contributed significantly to research, with multiple publications related to kidney disease in reputed journals, and is involved in clinical trials for developing new treatments. He is honored as a Fellow by the American Society of Nephrology.
Education & Training
University of Pennsylvania Health SystemFellowship, Nephrology, 1997 - 2001- University of Pennsylvania Health SystemResidency, Internal Medicine, 1995 - 1997
University of Rochester School of Medicine and DentistryClass of 1995
Brown UniversitySc.B., Biophysics, Magna cum Laude, 1983 - 1987
Certifications & Licensure
CA State Medical License 2015 - 2027
NY State Medical License 2025 - 2027
VT State Medical License 2025 - 2026
PA State Medical License 1996 - 2016
American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- Fellow (ASNF) American Society of Nephrology
Clinical Trials
- Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease Start of enrollment: 2016 Jun 27
Publications & Presentations
PubMed
- Therapeutic potential of urinary extracellular vesicles in delivering functional proteins and modulating gene expression for genetic kidney disease.Yi Huang, Ali Osouli, Hui Li, Megan Dudaney, Jessica Pham
Biomaterials. 2025-10-01 - 5 citationsFemale Protection Against Diabetic Kidney Disease Is Regulated by Kidney-Specific AMPK Activity.Hak Joo Lee, Liang Min, Jingli Gao, Shane Matta, Viktor Drel
Diabetes... 2024-07-01 - 9 citationsLong-term expandable mouse and human-induced nephron progenitor cells enable kidney organoid maturation and modeling of plasticity and disease.Biao Huang, Zipeng Zeng, Sunghyun Kim, Connor C Fausto, Kari Koppitch
Cell Stem Cell. 2024-06-06
Journal Articles
- Design and in vivo characterization of kidney-targeting peptide amphiphile micelles toward renal drug deliveryWang, J., Poon, C., Chin, D., Milkowski, S., Lu, V., Hallows, K.R., and Chung, E.J., Nano Res. 11(10): 5584-5595, 2018.
- Muc1 is protective during kidney ischemia-reperfusion injuryPastor-Soler, N.M., Sutton, T.A., Mang, H.E., Kinlough, C.L., Gendler, S.J., Madsen, C.S., Bastacky, S., Ho, J., Al-bataineh, M.M., Hallows, K.R., Singh, S., Monga, S...., Am. J. Physiol. Renal Physiol.
Authored Content
- MIF Matters: The Macrophage Migration Inhibitory Factor and Kidney InjurySeptember 2018
Press Mentions
World Kidney Day: Keck Medicine of USC Experts Discuss Kidney Health and ResearchMarch 8th, 2017
MIF Matters: The Macrophage Migration Inhibitory Factor and Kidney InjurySeptember 19th, 2018
Grant Support
- Effects of Combination Therapy with Tolvapatan and the Farnesoid X Receptor Agonist INT-747 on Hepatotoxicity, Metabolic and Injury Biomarkers, and Cystogenesis in ADPKDOtsuka Pharmaceuticals, Inc.2019–2020
- Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease (Clinical Trial Award)U.S. Department of Defense2015–2020
- Cellular Energy Pathways as Novel Targets for the Therapy of Autosomal Dominant Polycystic Kidney DiseaseU.S. Department of Defense2015–2018
- Mechanisms and Relevance of Sodium Transport Regulation by AMPKNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2012–2017
- Mechanisms And Relevance Of ENAC Regulation By AMP-ACTIVATED KinaseNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2011
- Mechanisms Of ENAC Regulation By AMP-ACTIVATED KinaseNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2005
- Mechanism Of Inhibition Of CFTR By AMP-ACTIVATED KinaseNational Institute Of Diabetes And Digestive And Kidney Diseases2002–2005
- Mechanism Of Inhibition Of CFTR By AMP-ACTIVATED KinaseNational Institute Of Diabetes And Digestive And Kidney Diseases2001
- Novel Interaction Of Amp-Kinase With CFTR C1 ChannelNational Institute Of Diabetes And Digestive And Kidney Diseases2000
- Novel Interaction Of Amp-Kinase With CFTR CL ChannelNational Institute Of Diabetes And Digestive And Kidney Diseases1999
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
